OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
If awarded, OST-HER2 would become the first listeria investigational medicinal product to be awarded the RMAT designation
RMAT designation reduces BLA application review time and permits augmented interactions with FDA to inform market access
NEW YORK, June 06, 2025--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review.
OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent publicly disclosed PRV sale, valued at $155 million, occurred in May 2025.
The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. Upon receipt of the Type D Meeting feedback, the Company intends to promptly request the End of Phase 2 meeting with FDA in which it will be seek agreement to allow it to begin a rolling BLA submission in the third quarter of 2025. The grant of the RMAT designation in the third quarter of 2025 complements the company's parallel efforts in other major markets, including Europe and the United Kingdom, where the company plans to seek EMA PRIME Designation and Conditional Market Access (CMA) applications.
In parallel to regulatory engagement and market access planning for OST-HER2, the Company is preparing for the late stage clinical development of other pipeline candidates. As such, the Company is well positioned for sustained growth across multiple therapeutic modalities.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602523393/en/
Contacts
OS Therapies Contact Information: Jack Doll410-297-7793Irpr@ostherapies.com
https://x.com/OSTherapies https://www.instagram.com/ostherapies/ https://www.facebook.com/OSTherapies/ https://www.linkedin.com/company/os-therapies/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Chocolate company recalls product nationwide for undeclared allergen
NEW YORK (PIX11) — Chocolate products have been recalled nationwide due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. The Pennsylvania-based distributor, Weaver Nut Company, Inc., has recalled its semi-sweet chocolate nonpareils with white or Christmas colored seeds, the advisory from the FDA says. More Local News People who have an allergy or severe sensitivity to milk could face serious or life-threatening allergic reactions if they consume the impacted products, the FDA warns. So far no illnesses have been reported. The issue was discovered through a wholesale customer who filed a complaint saying the shipment was misaligned with the product specifications. Lab tests confirmed the presence of milk in the product. More: Latest News from Around the Tri-State Consumers who have purchased the recalled product are urged not to eat it if they have a milk allergy and return it to the place of purchase for a full refund. Below is the list of lot codes for the affected chocolates. 47518 – Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) 204206 204207 204208 204209 204212 224225 D2645 – Nonpareils, Semi-Sweet Chocolate (White Seeds) 204214-RL 204214 204215 224221 224222 224223 135215 135216 135217 135220 135221 145204 145205-1 145207-1 145210-1 Dominique Jack is a digital content producer from Brooklyn with more than five years of experience covering news. She joined PIX11 in 2024. More of her work can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Chocolate Recalled Nationwide Due to Potential 'Life-Threatening Allergic Reaction': Here's What You Need to Know
A nationwide recall has been issued for JLM-brand Dark Chocolate Nonpareils due to a risk of 'serious or life-threatening allergic reaction," per the FDA The recall occurred after it was discovered that batches of the product may contain 'undeclared milk' No illnesses have currently been reported, and consumers who purchased the batches in question are urged to return them to the place of purchaseA nationwide recall has been issued for a common type of chocolate due to 'risk of serious or life-threatening allergic reaction,' according to the U.S. Food & Drug Administration (FDA). Michigan-based Lipari Foods is recalling its 14-ounce packages of JLM Branded 'Dark Chocolate Nonpareils" as they may contain "undeclared milk," per an announcement posted on the FDA's website on Friday, June 20. 'People who have allergies to milk run the risk of serious or life-threatening allergic reaction if they consume these products,' the announcement said. According to the FDA, the Dark Chocolate Nonpareils were distributed nationwide and also come in 14-ounce clear plastic tubs. The tubs in question will be marked with one of the following lot numbers on the label: 28202501A, 29202501A, 23202504A, 14202505A, 15202505A or 03202506A. No illnesses have been reported to date in connection with the recall, per the FDA. The organization additionally said that the recall occurred after Lipari Foods was notified of the error by the Pennsylvania-based Weaver Nut Company, which distributes and manufactures candy and nuts. The FDA is urging customers who have purchased the 14-ounce packages to return them to the place of purchase 'for a full refund.' PEOPLE reached out to Lipari Foods for comment on Saturday, June 21, but did not receive an immediate response. This isn't the first time that a nationwide recall of chocolate has been issued in recent months. In December 2024, Cal Yee Farms' recalled some of its chocolate products due to the fact that they potentially contained 'undeclared milk, soy, wheat, sesame, FD&C #6 and almonds.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. The FDA heightened the risk level of the recall earlier this year in January, after it was discovered that the products may also contain undeclared milk. Read the original article on People
Yahoo
6 hours ago
- Yahoo
Weaver Nut Company recalls chocolate nonpareils over undeclared allergens
Multiple batches of chocolate nonpareils produced by Weaver Nut Company, Inc. and sold across the U.S. have been recalled due to potential undeclared milk allergens, the Food and Drug Administration announced earlier this week. Six lots of semi-sweet chocolate with "Christmas Seeds" colored nonpareils, or small ball-shaped sprinkles, and 15 lots of semi-sweet chocolate with white nonpareils are included in the recall. The FDA said those with an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products listed below. 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds)Lot #(s): 204206, 204207, 204208, 204209, 204212, 224225 D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds)Lot #(s) 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1 No illnesses have been reported but the product was sold at various retail and grocery store outlets across the country, the FDA said. "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products," company spokesperson Angela Nolt said in the recall announcement. The issue was discovered after a wholesale customer made a complaint, according to the FDA. A following lab test later confirmed the presence of milk. Saturday Sessions: Grace Potter performs "Paris" Saturday Sessions: Grace Potter performs "Medicine" Saturday Sessions: Grace Potter performs "Before the Sky Falls"
